Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factors associated with slow progression in Huntington's disease.

R H Myers1, D S Sax, W J Koroshetz

  • 1Department of Neurology, Boston University School of Medicine, MA 02118.

Archives of Neurology
|August 1, 1991
PubMed
Summary

Older age at Huntington's disease onset and higher body mass index correlate with slower disease progression. Male patients, especially those inheriting the disease maternally, also showed slower progression, informing future clinical trial designs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide meta-analysis of variant-by-diuretic interactions as modulators of lipid traits in persons of European and African ancestry.

The pharmacogenomics journal·2019
Same author

Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology.

The pharmacogenomics journal·2017
Same author

Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group.

The pharmacogenomics journal·2016
Same author

Common variants associated with changes in levels of circulating free fatty acids after administration of glucose-insulin-potassium (GIK) therapy in the IMMEDIATE trial.

The pharmacogenomics journal·2015
Same author

Genetic modifiers of response to glucose-insulin-potassium (GIK) infusion in acute coronary syndromes and associations with clinical outcomes in the IMMEDIATE trial.

The pharmacogenomics journal·2015

Area of Science:

  • Neuroscience
  • Genetics
  • Clinical Neurology

Background:

  • Huntington's disease (HD) is a progressive neurodegenerative disorder.
  • Understanding factors influencing HD progression is crucial for therapeutic development.

Purpose of the Study:

  • To assess the rate of disease progression in Huntington's disease.
  • To identify factors associated with slower or faster progression.

Main Methods:

  • Longitudinal study of 42 Huntington's disease patients.
  • Neurological examinations (≥6) over a minimum of 3 years.
  • Disability rating scale administered at each examination.

Main Results:

  • Slower progression linked to older age at onset and higher baseline body mass index (BMI).

Related Experiment Videos

  • Men exhibited slower progression than women, particularly those with maternal inheritance.
  • Haloperidol, imipramine, depression, hostility, and tobacco use showed no correlation with progression rate.

    • Conclusions:

    • Age at onset, BMI, sex, and mode of inheritance are significant factors in Huntington's disease progression.
    • These factors should be considered in the design of clinical trials for Huntington's disease therapies.